Treatment of Topical Ketorolac Gel in Acute Gouty Flare

Status Not yet recruiting

Clinical Trial Summary

This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac tromethamine injection, USP (15mg/mL) comparator in healthy volunteers, including an evaluation of safety, tolerability, and efficacy in gout participants with flare-up.

Clinical Trial Description

Participants will be in the age range of 18 - 64 years of age (Cohort 1) and 18 - 70 years of age (Cohorts 2 and 3). This study will be conducted in three consecutive cohorts (see Figure 1). Cohorts 1 and 2 is conducted inpatient, while Cohort 3 is conducted outpatient. - Cohort 1: Open-label, single-day, multiple-dose (three doses), in approximately 8 adult healthy volunteers. Study participants will be admitted to the clinic and receive one intravenous dose of ketorolac tromethamine injection, USP over the course of one day for one treatment period, and three doses of topical drug product over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods of this Cohort 1. The next dose begins after a 2-day wash-out period, and there are three dose levels for the topically applied transcutaneous ketorolac tromethamine gel 12.5% (w/w) (NOV-1776) to be compared to one intravenous administration of 2 ml of ketorolac tromethamine injection, USP (5 mg/mL). Safety Review Committee meeting to review Cohort 1 data and approve continuance to Cohort 2. - Cohort 2: Open-label, 1-arm, 5-day, multiple-dose PK, safety in approximately 12 adult healthy volunteers at the maximum tolerated dose demonstrated by Cohort 1. Study participants will be admitted to the clinic and receive three doses of drug product, 6 hours apart, over the course of 5 days. Cohort 1 participants are eligible to participate in Cohort 2. Safety Review Committee meeting to review Cohort 1 and 2 data and approve continuance to Cohort 3. - Cohort 3 will be an open-label, 1-arm, 5-day, multiple-dose safety, toleration, and efficacy design in 10 adult gout participants with flare-up ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06273813
Study type	Interventional
Source	Novilla Pharmaceuticals
Contact	Novotech CRO
Phone	+61 2 8569 1400
Email	info@novotech.com
Status	Not yet recruiting
Phase	Phase 1
Start date	February 2024
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04484610` - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study	Phase 4
Recruiting	`NCT05054179` - Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain	Phase 2/Phase 3
Completed	`NCT04548635` - VR for Burn Dressing Changes at Home	Phase 2/Phase 3
Recruiting	`NCT05370404` - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:	N/A
Completed	`NCT06054945` - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed	`NCT03825549` - A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing	N/A
Completed	`NCT05995912` - Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain	Phase 2
Recruiting	`NCT05589246` - Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure	N/A
Recruiting	`NCT05572190` - Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects	Phase 1
Terminated	`NCT04716413` - Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment	Phase 4
Active, not recruiting	`NCT03537573` - Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care	N/A
Not yet recruiting	`NCT06317844` - Examination of Psychological and Physiological Pathways Linking Gratitude and Pain	N/A
Withdrawn	`NCT02957097` - Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures	Phase 4
Completed	`NCT02565342` - Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery	Phase 4
Terminated	`NCT02599870` - Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures	N/A
Completed	`NCT02984098` - 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose	Phase 4
Completed	`NCT02380989` - Integrative Ayurveda Healing Relieves Minor Sports Injury Pain	Phase 2
Completed	`NCT03107338` - Preventive Treatment of Pain After Dental Implant Surgery	Phase 4
Completed	`NCT02489630` - Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department	Phase 4
Completed	`NCT02817477` - Intranasal Ketamine for Acute Traumatic Pain	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.